Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity.

Autor: Sabatino JJ Jr; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Mittl K; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Rowles W; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Mcpolin K; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Rajan JV; Division of Experimental Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA., Zamecnik CR; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Dandekar R; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Alvarenga BD; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Loudermilk RP; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Gerungan C; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Spencer CM; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Sagan SA; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Augusto DG; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.; Programa de Pós-Graduação em Genética, Universidade Federal do Paraná, Curitiba, Brazil., Alexander J; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Hollenbach JA; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA., Wilson MR; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Zamvil SS; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA., Bove R; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
Jazyk: angličtina
Zdroj: MedRxiv : the preprint server for health sciences [medRxiv] 2021 Sep 20. Date of Electronic Publication: 2021 Sep 20.
DOI: 10.1101/2021.09.10.21262933
Abstrakt: Vaccine-elicited adaptive immunity is an essential prerequisite for effective prevention and control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse array of disease-modifying therapies (DMTs) that target antibody and cell-mediated immunity, yet a comprehensive understanding of how MS DMTs impact SARS-CoV-2 vaccine responses is lacking. We completed a detailed analysis of SARS-CoV-2 vaccine-elicited spike antigen-specific IgG and T cell responses in a cohort of healthy controls and MS participants in six different treatment categories. Two specific DMT types, sphingosine-1-phosphate (S1P) receptor modulators and anti-CD20 monoclonal antibodies (mAb), resulted in significantly reduced spike-specific IgG responses. Longer duration of anti-CD20 mAb treatment prior to SARS-CoV-2 vaccination were associated with absent antibody responses. Except for reduced CD4+ T cell responses in S1P-treated patients, spike-specific CD4+ and CD8+ T cell reactivity remained robust across all MS treatment types. These findings have important implications for clinical practice guidelines and vaccination recommendations in MS patients and other immunosuppressed populations.
Databáze: MEDLINE